Terazosin

Summary

Terazosin (CHEMBL611) is an approved small-molecule antineoplastic agent (ATC G04CA03) targeting ADRA1A, ADRA1B, and ADRA1D; indicated across 8 conditions including benign prostatic hyperplasia and hypertensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04CA03
• Targets: 3 (ADRA1A, ADRA1B, ADRA1D)
• Indications: 8 conditions
• Clinical trials: 16
• Chemistry: 387.4 Da · C19H25N5O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL611
Name	Terazosin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5401
ChEBI	CHEBI:9445
ATC	G04CA03
Molecular formula	C19H25N5O4
Molecular weight	387.4
InChIKey	VCKUSRYTPJJLNI-UHFFFAOYSA-N

SMILES: COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC

IUPAC name: [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone

Pharmacological roles (ChEBI): antineoplastic agent, antihypertensive agent, α-adrenergic antagonist.

Also known as: Terazosabb, Terazosin, Terazosina, Terazosine, terazosin, Terazocin, SID855611, SID90340975, SID50085853, TERAZOSINE, SID174007477, TERAZOSIN

Parent form; salt/anhydrous children: CHEMBL1201091, CHEMBL1256665, CHEMBL3989562

Patent coverage: 5,041 distinct patent families (18,696 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 18,690 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRA1A	α1A-adrenoceptor	Antagonist	8.2		P35348
ADRA1B	α1B-adrenoceptor	Antagonist	8.7	0%	P35368
ADRA1D	α1D-adrenoceptor	Antagonist	8.6	0.2%	P25100

Broader ChEMBL bioactivity targets: 31 (assay-derived). Sample: Lysine-specific demethylase 4E, Survival motor neuron protein, Prelamin-A/C, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], ATP-binding cassette sub-family C member 4, Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Beta-lactamase, D(1A) dopamine receptor, Adrenergic receptor alpha-1, Acetylcholinesterase, Alpha-1D adrenergic receptor, Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Mu-type opioid receptor, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Alpha-galactosidase A.

Bioactivity

ChEMBL activities: 104 potent at pChembl ≥ 5 of 118 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA1B	9.3	EC50	0.5	nM	CHEMBL_ACT_15186194
P18841	9.16	Ki	0.69	nM	CHEMBL_ACT_831822
P43140	9.09	Ki	0.82	nM	CHEMBL_ACT_831821
ADRA1D	9.07	Ki	0.85	nM	CHEMBL_ACT_57647
P23944	9	Ki	1.01	nM	CHEMBL_ACT_831823
ADRA1B	8.92	Ki	1.2	nM	CHEMBL_ACT_1000375
ADRA1B	8.92	Ki	1.2	nM	CHEMBL_ACT_473825
P23944	8.83	Kd	1.48	nM	CHEMBL_ACT_15211919
P23944	8.83	Kd	1.48	nM	CHEMBL_ACT_18496924
ADRA1B	8.76	EC50	1.73	nM	CHEMBL_ACT_16764915
P15823	8.72	Ki	1.9	nM	CHEMBL_ACT_1000372
ADRA1B	8.72	Ki	1.9	nM	CHEMBL_ACT_303826
ADRA1B	8.72	Ki	1.9	nM	CHEMBL_ACT_677848
ADRA1B	8.71	Ki	1.95	nM	CHEMBL_ACT_338934
ADRA1D	8.7	Ki	2	nM	CHEMBL_ACT_1000376
ADRA1D	8.7	Ki	2	nM	CHEMBL_ACT_473824
ADRA1A	8.7	Ki	2	nM	CHEMBL_ACT_473830
ADRA1A	8.7	Ki	2	nM	CHEMBL_ACT_57645
ADRA1B	8.66	Ki	2.2	nM	CHEMBL_ACT_319204
P15823	8.65	Kd	2.24	nM	CHEMBL_ACT_13351504
P23944	8.65	Kd	2.24	nM	CHEMBL_ACT_18496951
P23944	8.65	Kd	2.24	nM	CHEMBL_ACT_57654
ADRA1A	8.62	Ki	2.4	nM	CHEMBL_ACT_473828
P18130	8.6	Ki	2.51	nM	CHEMBL_ACT_1213818
P15823	8.6	Kd	2.51	nM	CHEMBL_ACT_18496950
ADRA1B	8.6	Ki	2.51	nM	CHEMBL_ACT_274835
P15823	8.6	Kd	2.51	nM	CHEMBL_ACT_57653
P15823	8.6	Kd	2.51	nM	CHEMBL_ACT_832807
P15823	8.59	Kd	2.57	nM	CHEMBL_ACT_15211906
P15823	8.59	Kd	2.57	nM	CHEMBL_ACT_18496917
ADRA1B	8.59	Ki	2.6	nM	CHEMBL_ACT_610323
ADRA1B	8.57	Ki	2.68	nM	CHEMBL_ACT_57646
ADRA1A	8.54	Ki	2.9	nM	CHEMBL_ACT_473827
P15823	8.48	Ki	3.33	nM	CHEMBL_ACT_7799707
P23944	8.47	Ki	3.4	nM	CHEMBL_ACT_1000373
ADRA1D	8.46	Ki	3.5	nM	CHEMBL_ACT_303827
ADRA1D	8.46	Ki	3.5	nM	CHEMBL_ACT_319202
ADRA1D	8.46	Ki	3.47	nM	CHEMBL_ACT_338935
ADRA1D	8.46	Ki	3.5	nM	CHEMBL_ACT_677849
ADRA1D	8.43	Ki	3.7	nM	CHEMBL_ACT_610324
P43140	8.41	Ki	3.9	nM	CHEMBL_ACT_1000371
ADRA1D	8.4	Ki	3.98	nM	CHEMBL_ACT_274836
ADRA1A	8.4	Ki	4	nM	CHEMBL_ACT_303828
ADRA1A	8.38	Ki	4.2	nM	CHEMBL_ACT_1000374
ADRA1A	8.38	Ki	4.2	nM	CHEMBL_ACT_473826
ADRA1D	8.3	IC50	5	nM	CHEMBL_ACT_24959148
P15823	8.22	IC50	6.03	nM	CHEMBL_ACT_7799706
ADRA1A	8.16	Ki	6.9	nM	CHEMBL_ACT_303825
ADRA1A	8.16	Ki	6.92	nM	CHEMBL_ACT_338933
ADRA1A	8.16	Ki	6.9	nM	CHEMBL_ACT_354747
ADRA1A	8.16	Ki	6.9	nM	CHEMBL_ACT_610322
ADRA1A	8.16	Ki	6.9	nM	CHEMBL_ACT_677847
ADRA1A	8.14	Ki	7.3	nM	CHEMBL_ACT_319206
P19328	8.11	Ki	7.7	nM	CHEMBL_ACT_57649
ADRA1D	8.08	Ki	8.36	nM	CHEMBL_ACT_7799709
P43140	8.04	Kd	9.12	nM	CHEMBL_ACT_18496949
P43140	8.04	Kd	9.12	nM	CHEMBL_ACT_57652
P43140	8.04	Kd	9.12	nM	CHEMBL_ACT_832806
P43140	8.02	Ki	9.59	nM	CHEMBL_ACT_7799705
ADRA1A	7.99	AC50	10.3	nM	CHEMBL_ACT_25138431
P43140	7.9	Kd	12.59	nM	CHEMBL_ACT_15211893
P43140	7.9	Kd	12.59	nM	CHEMBL_ACT_18496910
ADRA1D	7.77	IC50	17	nM	CHEMBL_ACT_7799708
ADRA1A	7.73	AC50	18.6	nM	CHEMBL_ACT_25137948
O02824	7.7	Kd	19.95	nM	CHEMBL_ACT_1213820
P43140	7.62	IC50	24	nM	CHEMBL_ACT_7799704
ADRA1D	7.6	Kd	25.12	nM	CHEMBL_ACT_1213819
P18130	7.58	Ki	26	nM	CHEMBL_ACT_319207
ADRA2B	7.58	Ki	26	nM	CHEMBL_ACT_610326
ADRA1B	7.52	Ki	30	nM	CHEMBL_ACT_319205
ADRA2B	7.51	Ki	30.9	nM	CHEMBL_ACT_338937
ADRA1A	7.5	Ki	32	nM	CHEMBL_ACT_473829
P23944	7.46	Ki	35	nM	CHEMBL_ACT_319203
ADRA1A	7.44	Kd	36.31	nM	CHEMBL_ACT_57651
ADRA1A	7.44	Kd	36.31	nM	CHEMBL_ACT_832808
ADRA1A	7.4	Ki	39.81	nM	CHEMBL_ACT_274834
ADRA1D	7.4	Kd	39.81	nM	CHEMBL_ACT_274840
ADRA1A	7.29	EC50	51	nM	CHEMBL_ACT_15186187
ADRA1A	7.29	EC50	51.89	nM	CHEMBL_ACT_16764855
ADRA2C	7.11	Ki	78	nM	CHEMBL_ACT_57650
LMNA	6.95	Potency	112.2	nM	CHEMBL_ACT_3627800
ADRA2C	6.77	Ki	170	nM	CHEMBL_ACT_610327
ADRA2B	6.71	Ki	195	nM	CHEMBL_ACT_7799713
ADRA2C	6.67	Ki	213	nM	CHEMBL_ACT_319210
ADRA2C	6.65	Ki	223.9	nM	CHEMBL_ACT_338938
ADRA1A	6.5	AC50	320	nM	CHEMBL_ACT_25218093
ADRA2C	6.46	AC50	350	nM	CHEMBL_ACT_25147909
ADRA1A	6.44	AC50	360	nM	CHEMBL_ACT_25218985
ADRA2B	6.4	AC50	400	nM	CHEMBL_ACT_25143734
ADRA2B	6.38	Ki	418	nM	CHEMBL_ACT_319209
ADRA2B	6.37	IC50	428	nM	CHEMBL_ACT_7799712
ADRA2A	6.26	Ki	549.5	nM	CHEMBL_ACT_338936
ADRA2A	6.26	Ki	550	nM	CHEMBL_ACT_610325
KDM4E	6.2	Potency	631	nM	CHEMBL_ACT_3705372
ADRA2C	6.06	Ki	878	nM	CHEMBL_ACT_7799715
ADRA2A	5.82	Ki	1500	nM	CHEMBL_ACT_57648
OPRK1	5.63	AC50	2363	nM	CHEMBL_ACT_25129453
OPRM1	5.52	AC50	3000	nM	CHEMBL_ACT_25157470
ADRA2A	5.43	Ki	3702	nM	CHEMBL_ACT_319208
SMN1	5.4	Potency	3981	nM	CHEMBL_ACT_3863881

Target pathways

Aggregated over 3 target gene(s): ADRA1A, ADRA1B, ADRA1D.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	3	ADRA1A, ADRA1B, ADRA1D
Signaling by GPCR	3	ADRA1A, ADRA1B, ADRA1D
Class A/1 (Rhodopsin-like receptors)	3	ADRA1A, ADRA1B, ADRA1D
Amine ligand-binding receptors	3	ADRA1A, ADRA1B, ADRA1D
GPCR downstream signalling	3	ADRA1A, ADRA1B, ADRA1D
Adrenoceptors	3	ADRA1A, ADRA1B, ADRA1D
G alpha (q) signalling events	3	ADRA1A, ADRA1B, ADRA1D
G alpha (12/13) signalling events	3	ADRA1A, ADRA1B, ADRA1D
GPCR ligand binding	3	ADRA1A, ADRA1B, ADRA1D

Dominant GO biological processes

GO term	Targets
signal transduction	3
G protein-coupled receptor signaling pathway	3
phospholipase C-activating G protein-coupled receptor signaling pathway	3
positive regulation of cytosolic calcium ion concentration	3
cell-cell signaling	3
positive regulation of MAPK cascade	3
adenylate cyclase-activating adrenergic receptor signaling pathway	3
neuron-glial cell signaling	3
adrenergic receptor signaling pathway	3
positive regulation of cardiac muscle hypertrophy	2
intracellular signal transduction	2
positive regulation of vasoconstriction	2
regulation of muscle contraction	2
regulation of vasoconstriction	2
regulation of cardiac muscle contraction	2

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
benign prostatic hyperplasia	4	MONDO:0010811	EFO:0000284

6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hypertensive disorder	3	MONDO:0005044	EFO:0000537
atherosclerosis	3	MONDO:0005311	EFO:0003914
coronary artery disorder	3	MONDO:0005010	EFO:0001645
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
internal carotid artery stenosis	2	MONDO:0005189	EFO:0002615
Parkinson disease	1	MONDO:0005180	MONDO:0005180

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE2	4
Not specified	4
PHASE4	2
PHASE3	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05855577	PHASE4	NOT_YET_RECRUITING	Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson’s Patients
NCT00449683	PHASE4	COMPLETED	Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin
NCT06966804	PHASE3	RECRUITING	Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms
NCT07207057	PHASE3	RECRUITING	Edmond J. Safra Accelerating Clinical Trials in Parkinson’s Disease: A Multiarm Multi-stage Platform Trial
NCT01530243	PHASE2/PHASE3	COMPLETED	The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
NCT04386317	PHASE2	ACTIVE_NOT_RECRUITING	Terazosin Effect on Cardiac Changes in Early Parkinson’s Disease
NCT05109364	PHASE2	ACTIVE_NOT_RECRUITING	Terazosin and Parkinson’s Disease Extension Study
NCT07464028	PHASE2	NOT_YET_RECRUITING	Terazosin And Metabolic Energetics in Parkinson’s Disease
NCT03195673	PHASE2	UNKNOWN	Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting
NCT03905811	PHASE1/PHASE2	COMPLETED	A Pilot Study of Terazosin for Parkinson’s Disease
NCT04551040	PHASE1	ACTIVE_NOT_RECRUITING	Target Engagement of Terazosin in Healthy Adults
NCT07224269	EARLY_PHASE1	NOT_YET_RECRUITING	Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis
NCT00237510	Not specified	COMPLETED	Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating
NCT00563485	Not specified	TERMINATED	Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
NCT00693199	Not specified	COMPLETED	Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension
NCT01508637	Not specified	UNKNOWN	Diesel Exhaust and Vascular Function

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

571 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ALFUZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
AMLODIPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
APRACLONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ASENAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ATENOLOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BRIMONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BUSPIRONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CISAPRIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CLONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CLOZAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
DEXMEDETOMIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
DOPAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
DOXAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
EBASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
EPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
FENOLDOPAM	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
INDACATEROL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
INDORAMIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
LABETALOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
MOXISYLYTE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
NAFTOPIDIL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
NOREPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
OLANZAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
PHENTOLAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
PRAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
QUETIAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
SERTINDOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
SILODOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TAMSULOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TEGASEROD	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TERFENADINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TOLAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
VERAPAMIL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
VILAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
XYLOMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BUNAZOSIN	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
IDAZOXAN	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
LATREPIRDINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
MEDETOMIDINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
YOHIMBINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
ABANOQUIL	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
CIRAZOLINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
DEXNIGULDIPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
IPSAPIRONE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
MAZAPERTINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
NIGULDIPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
PIPEROXAN	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
PIZOTYLINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
SPIRAMIDE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
SPIROXATRINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
TASIPIMIDINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
UPIDOSIN	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
ZOTEPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
APOMORPHINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
BENZTROPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CINNARIZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CITALOPRAM	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
DAPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
DOBUTAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
DOMPERIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
DOXEPIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
ERGOTAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
FENTANYL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
GUANABENZ	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
GUANFACINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
IMIQUIMOD	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
KETOTIFEN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
LOPERAMIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B
LUMATEPERONE TOSYLATE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B
MAPROTILINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
MEPAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
MIANSERIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
PERGOLIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
PHENYLEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D